On November 6, 2019 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that seven abstracts covering data from the company’s research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando (Press release, GlycoMimetics, NOV 6, 2019, View Source [SID1234550468]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Of particular note, clinical data from the Company’s recent Phase 1/2 study of uproleselan, an E-selectin antagonist and the company’s lead wholly owned clinical candidate, were selected for a poster presentation on Sunday, December 8 during a session on biology of AML. The presentation will feature data showing uproleselan’s ability to reverse chemoresistance in patients who have high-risk clinical features and over-express the E-selectin ligand. The poster presentation will highlight the potential benefits of this novel candidate, which resulted in an overall survival of 12.7 months in a high-risk group of patients when added to salvage chemotherapy – longer than expected survival based on clinical variables alone.

A poster presentation of complementary work by investigators at the Fred Hutchinson Cancer Research Center will highlight research identifying the unique gene expression signature that is a surrogate for E-selectin ligand expression on leukemic cells. For the first time, in a large clinical database, independent analysis of glycogene signature demonstrated that E-selectin ligand expression is associated with poor survival in pediatric patients with AML.

"The collective data from this year’s posters and presentations support the fact that E-selectin plays a major role in chemoresistance in AML, and we are excited to share results showing that uproleselan can counter resistance by augmenting deep clinical responses – and ultimately may prolong survival," said GlycoMimetics Senior Vice President of Clinical Development and Chief Medical Officer Helen Thackray, M.D., FAAP. "As a pioneer in the field of environment-mediated drug resistance in oncology, the GlycoMimetics team is applying its proprietary technology to discover and develop drugs that target these pathways. In addition, we are actively studying key related biomarkers in multiple cancers and exploring additional ways to incorporate these recent discoveries into our development program."

Other GlycoMimetics presentations will showcase research on how the E-selectin binding potential of AML blasts is altered during therapy and how these variations influence treatment outcomes, as well as investigations into which AML cell surface receptors mediate E-selectin induced chemo-resistance.

Presentation Details:

Publication Number: 2690
TITLE: High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan
Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Session Date: Sunday, December 8, 2019
Presentation Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall B

Publication Number: 2650
TITLE: A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Session Date: Sunday, December 8, 2019
Presentation Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall B

Publication Number: 1366
TITLE: A Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Session Date: Saturday, December 7, 2019
Presentation Time: 5:30 PM – 7:30 PM EST
Location: Orange County Convention Center, Hall B

Publication Number: 3802
TITLE: Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
Session Name: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III
Session Date: Monday, December 9, 2019
Presentation Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall B

Publication Number: 907
TITLE: CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Cell-Cell Interactions, Surface Antigens, and Mitochondria
Session Date: Monday, December 9, 2019
Session Time: 6:15 PM – 7:45 PM EST
Presentation Time: 6:15 PM EST
Room: Orange County Convention Center, W308

Publication Number: 2657
TITLE: Blocking Vascular Niche E-Selectin Dampens AML Stem Cell Regeneration/Survival Potential In Vivo By Inhibiting MAPK/ERK and PI3K/AKT Signaling Pathways
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Session Date: Sunday, December 8, 2019
Presentation Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall B

Publication Number: 3772
TITLE: Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-selectin Ligand Expression and Clinical Outcome
Session Name: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III
Session Date: Monday, December 9, 2019
Presentation Time: 6:00 PM – 8:00 PM
Location: Orange County Convention Center, Hall B

Meeting abstracts are available on ASH (Free ASH Whitepaper)’s website.

About Uproleselan (GMI-1271)

Uproleselan (yoo’ pro le’ sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed or refractory patients with AML. In both populations, patients treated with uproleselan together with standard chemotherapy achieved better-than-expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials evaluating standard chemotherapy, as well as lower-than-expected induction-related mortality rates. Treatment in these patient populations was generally well tolerated, with fewer than expected adverse effects.